 |
4 Diseases |  |
49 Trials |
|
49 Trials |  |
1092 News |  |
| «12...45678910111213141516» |
- || relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
ORR 43% for nivolumab + relatlimab vs 32% for nivo alone (statistically significant difference) (Twitter) - Mar 15, 2022
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Consistent progression free survival results with anti-#LAG3 #relatlimab plus #nivolumab in #melanoma. Median PFS 10.2 mo vs. 4.6 mo. Response 43.1% vs. 32.6% Complete responses 16.3% vs. 14.2%. Overall survival HR 0.80; P=0.059; 24 mo 63.7% vs. 58.3%. https://t.co/liZYwkMWGH (Twitter) - Mar 15, 2022
- relatlimab (BMS-986016) / BMS, Ono Pharma, Anike (penpulimab) / Akesobio, Sino Biopharm, cadonilimab (AK104) / Akesobio
AK129, an anti-PD1/LAG-3 bi-specific antibody for cancer therapy (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7046;
AK129 has demonstrated robust anti-tumor activity in both in vivo and in vitro pre-clinical studies, and with enhanced T cell activity compared to PD-1 and LAG-3 antibody combo. The efficacy and safety of AK129 await testing in the clinic.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Patients with operable esophageal cancer and improved responses to combined chemoradiotherapy and immunotherapy display distinct microbiome profiles enriched in multiple Bacteroides species (Section 31) - Mar 9, 2022 - Abstract #AACR2022AACR_3861;
P1
Patients with operable esophageal cancer and improved responses to combined CRT and IO had distinct microbiome profiles enriched in multiple Bacteroides species. Further analyses and validation efforts are underway to confirm metabolomic pathways.
- || Enrollment closed, Trial completion date: FRACTION-RCC: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Mar 9, 2022
P2, N=155, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Further analyses and validation efforts are underway to confirm metabolomic pathways. Recruiting --> Active, not recruiting | Trial completion date: Jan 2023 --> Jan 2024
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Checkpoint inhibition: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov) - Mar 2, 2022
P1, N=20, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Active, not recruiting | Trial completion date: Jan 2023 --> Jan 2024 Completed --> Active, not recruiting | Trial completion date: Jan 2022 --> Dec 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
- || Opdivo (nivolumab) / BMS
Trial primary completion date, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Feb 25, 2022
P1/2, N=584, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Completed --> Active, not recruiting | Trial completion date: Jan 2022 --> Dec 2024 | Trial primary completion date: Jan 2022 --> Jan 2024 Trial primary completion date: Sep 2021 --> Mar 2021
- || relatlimab (BMS-986016) / BMS, Ono Pharma, eftilagimod alpha (IMP 321) / Immutep
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. (Pubmed Central) - Feb 24, 2022
Finally, high FGL1 and LAG3 expression induces EGFR-TKI and gefitinib resistance, and anti-PD-1 therapy resistance, respectively. We present a comprehensive overview of the role of LAG3/FGL1 in cancer, suggesting novel anti-tumor therapy strategies.
- |||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P1/2 trial: RELATIVITY-069: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 23, 2022
P1/2, N=68, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, IO biomarker: NESCIO: Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (clinicaltrials.gov) - Feb 20, 2022
P2, N=69, Recruiting, Sponsor: The Netherlands Cancer Institute
We present a comprehensive overview of the role of LAG3/FGL1 in cancer, suggesting novel anti-tumor therapy strategies. Not yet recruiting --> Recruiting
- | Biomarker, Trial completion date, Trial primary completion date: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Feb 18, 2022
P2, N=6452, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Jun 2022 --> Dec 2025 | Trial primary completion date: Jun 2022 --> Dec 2025
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Feb 11, 2022
P1/2, N=1499, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jun 2022 --> Dec 2025 | Trial primary completion date: Jun 2022 --> Dec 2025 Trial primary completion date: Nov 2021 --> Sep 2022
- || Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion date, Trial primary completion date: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Feb 8, 2022
P1/2, N=77, Recruiting, Sponsor: Celgene
Trial primary completion date: Nov 2021 --> Sep 2022 Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025
- | Biomarker, Trial primary completion date: ADVISE: An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (clinicaltrials.gov) - Feb 7, 2022
P1, N=50, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025 Trial primary completion date: Mar 2021 --> Mar 2022
- ||| Enrollment change: RELATIVITY-048: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Feb 6, 2022
P1/2, N=255, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2021 --> Mar 2022 N=184 --> 255
- | Trial completion date: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Feb 3, 2022
P2, N=190, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=184 --> 255 Trial completion date: Dec 2023 --> May 2023
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: CONGRATS: Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study (clinicaltrials.gov) - Feb 2, 2022
P2, N=67, Recruiting, Sponsor: Institut Bergoni
Trial completion date: Dec 2023 --> May 2023 Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Mar 2022 --> Aug 2023
- || relatlimab (BMS-986016) / BMS, Ono Pharma
Has relatlimab been approved? (Twitter) - Jan 28, 2022
- | Journal: Antibodies to watch in 2022. (Pubmed Central) - Jan 27, 2022
Finally, our data show that, with antibodies for COVID-19 excluded, the late-stage commercial clinical pipeline of antibody therapeutics grew by over 30% in the past year. Of those in late-stage development, marketing applications for at least 22 may occur by the end of 2022.
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma
Clinical: with the current approvals of PD1 in second line, tebentefusp in ocular melanoma, and RELATLIMAB in metastatic melanoma there is much to learn and #work to do. 35% off reistration with code #IME22OH (Twitter) - Jan 26, 2022
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Combination therapy: #Relatlimab and #nivolumab combination therapy showed improved PFS compared to nivolumab alone in patients with untreated metastatic #melanoma! Check out the article in @NEJM by @HTawbi_MD, @ProfGLongMIA and colleagues ➡️ https://t.co/Yu5LC6DYG1 (Twitter) - Jan 25, 2022
- | relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical Trial,Phase III, Journal: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. (Pubmed Central) - Jan 20, 2022
P2/3
Relatlimab and nivolumab in combination showed no new safety signals. (Funded by Bristol Myers Squibb; RELATIVITY-047 ClinicalTrials.gov number, NCT03470922.).
- |||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Checkpoint inhibition: Relatlimab & Nivolumab vs Nivolumab in Untreated Advanced Melanoma: 2 checkpoint inhibitors LAG-3 + PD1 provide greater benefit for PFS than inhibition of PD1 alone with nivolumab. Provocative new positive outcome signal in our metastatic melanoma pts https://t.co/E4bLupyWXj (Twitter) - Jan 20, 2022
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: CLINICAL TRIAL: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma @MDAndersonNews @HTawbi_MD @ProfGLongMIA Originally published in @NEJM. To read our summary, click https://t.co/uQU5ruFIAO and scroll all the way down. (Twitter) - Jan 19, 2022
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Very excited to see this new trial data on combo aPD-1+aLAG3. Hoping our old work (Blackburn NI 2009) helped a little in getting this combo to patients. #reinvigoratingTex Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma | NEJM https://t.co/oyJTUMTt3x (Twitter) - Jan 10, 2022
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Checkpoint inhibition: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov) - Jan 10, 2022
P1, N=18, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
(Funded by Bristol Myers Squibb; RELATIVITY-047 ClinicalTrials.gov number, NCT03470922.). Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Jan 2022
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma | @NEJM | @HTawbi_MD et al @MDAndersonNews #endcancer https://t.co/mXbFdqZYfK (Twitter) - Jan 8, 2022
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Great read by @HTawbi_MD et al: Relatlimab and nivolumab vs nivolumab in untreated advanced melanoma. My takeaways + analysis (not peer-reviewed) @OncoAlert @NEJM 1/n (Twitter) - Jan 8, 2022
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Relatlimab Plus Nivolumab Improves Progression-Free Survival In Metastatic Melanoma https://t.co/TsfMbppZ9O #OBRoncology via @OBRTweets (Twitter) - Jan 6, 2022
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
#NEJM Relatlimab (LAG3) plus nivolumab improves progression-free survival in metastatic melanoma https://t.co/BgYhB9pxIG (Twitter) - Jan 6, 2022
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma | NEJM https://t.co/VkdZKrJ0e1 (Twitter) - Jan 6, 2022
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma | @NEJM @HTawbi_MD https://t.co/PRfEzGJ5Ap (Twitter) - Jan 5, 2022
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Checkpoint inhibition: On behalf of my colleagues, so excited to bring a new and safer immune checkpoint inhibitor combination to our patients with advanced melanoma, Relatlimab (anti-LAG3) with nivolumab improves PFS, minor increase in toxicity, new frontiers for #Immunotherapy https://t.co/Sp2XCk7xzk (Twitter) - Jan 5, 2022
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
⭐️🔺Just in 👉🏼 LAG3 emerges as #Immunotherapy after PD1/PDL1 & CTLA4 👉🏼Relatlimab + Nivolumab versus Nivolumab in Untreated Advanced Melanoma ! @nejm @HTawbi_MD @MDAndersonNews https://t.co/yXo9UOlfcV (Twitter) - Jan 5, 2022
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Checkpoint inhibition: Immune checkpoint inhibitors relatlimab plus nivolumab doubled the progression-free survival benefit in patients with untreated, advanced melanoma compared to a nivolumab alone, according to a study by our Dr. Hussein Tawbi: https://t.co/8YMFkJnKyu @HTawbi_MD #EndCancer (Twitter) - Jan 5, 2022
- ||| zanzalintinib (XL092) / Exelixis
New P1 trial: STELLAR-002: Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (clinicaltrials.gov) - Jan 3, 2022
P1, N=826, Recruiting, Sponsor: Exelixis
- |||||| relatlimab (BMS-986016) / BMS, Ono Pharma
New trial: Expanded Access for Relatlimab (clinicaltrials.gov) - Dec 28, 2021
P=N/A, N=0, Available, Sponsor: Bristol-Myers Squibb
- || Clinical, Journal, Checkpoint inhibition: The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. (Pubmed Central) - Dec 18, 2021
Promising antitumor activity was observed for escalation to lenvatinib plus pembrolizumab, entinostat plus pembrolizumab, and relatlimab plus nivolumab. Retreatment, rechallenge and escalation are available options for patients with melanoma who relapse in the adjuvant or advanced setting.
- | relatlimab (BMS-986016) / BMS, Ono Pharma, Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: A new approach to produce IgG-like bispecific antibodies. (Pubmed Central) - Dec 16, 2021
In vitro functional assay demonstrated that the purified bispecific antibody exhibits an enhanced agonist activity compared to that of the parental antibodies. Low immunogenicity was predicted by an open-access software and ADA test.
- |||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, IO biomarker: NESCIO: Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (clinicaltrials.gov) - Dec 7, 2021
P2, N=69, Not yet recruiting, Sponsor: The Netherlands Cancer Institute
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Multicenter phase II study of neoadjuvant nivolumab or nivolumab plus relatlimab (anti-LAG3 antibody) plus chemoradiotherapy in stage II/III esophageal/gastroesophageal junction (E/GEJ) carcinoma. (Live Stream | Level 1, West Hall; Poster Board - G4) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_108;
P1
In this study, neoadjuvant anti PD-1/LAG3 combination IO-IO strategies with CRT were challenging due to enhanced IR toxicities. In depth immune correlates and liquid biopsy analyses will be presented.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
TRIAL IN PROGRESS: NIVOLUMAB AND RELATLIMAB IN PATIENTS WITH ADVANCED CHORDOMA ([VIRTUAL]) - Nov 26, 2021 - Abstract #CTOS2021CTOS_344;
In depth immune correlates and liquid biopsy analyses will be presented. The trial is ongoing and accruing patients.
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
New P2 trial, Immuno-oncology: Study in kidney cancer patients with at least the kidney tumor present and sometimes enlarged lymph nodes in the vicinity of the affected kidney, in which the subjects first receive an immunotherapy treatment, which may consist of either nivolumab alone, or the combination of nivolumab and ipilimumab, or the combination of nivolumab and relatlimab, after which the kidney tumor (and possibly enlarged lymph nodes) is removed. (EUDRACT) - Nov 25, 2021
P2, N=69, Ongoing, Sponsor: Antoni van Leeuwenhoek ziekenhuis
- || Opdivo (nivolumab) / BMS
Trial primary completion date, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Nov 17, 2021
P1/2, N=584, Active, not recruiting, Sponsor: Bristol-Myers Squibb
The trial is ongoing and accruing patients. Trial primary completion date: Aug 2022 --> Sep 2021
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Wonder whether we can get away with Nivo+ Relatlimab than Nivo+ Ipi in non - CNS pts, from a toxicity standpoint.. (Twitter) - Nov 16, 2021
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment closed, Trial primary completion date: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 1, 2021
P1, N=35, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2022 --> Sep 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2021 --> Sep 2022
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment closed: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Nov 1, 2021
P1/2, N=1499, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2021 --> Sep 2022 Recruiting --> Active, not recruiting
- | Trial completion date: RELATIVITY-048: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Nov 1, 2021
P1/2, N=184, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Trial completion date: Feb 2023 --> Jul 2024
- || Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Oct 18, 2021
P2, N=385, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Feb 2023 --> Jul 2024 Trial completion date: Jul 2022 --> Mar 2024 | Trial primary completion date: Jul 2022 --> Mar 2023
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Exciting activity of Relatlimab/Nivolumab in metastatic melanoma. Excited to think about application in GU malignancies. @ALLIANCE_org @DrChoueiri https://t.co/yTUZiaWqii (Twitter) - Oct 17, 2021